BioProject

Individuals with the ALS-linked (amyotrophic lateral sclerosis) truncation mutation (R495X) in FUS (fused in sarcoma) are known to have a more aggressive form of the disease than those with point mutations. More...

Individuals with the ALS-linked (amyotrophic lateral sclerosis) truncation mutation (R495X) in FUS (fused in sarcoma) are known to have a more aggressive form of the disease than those with point mutations. The underlying cause for this difference is unclear. We report that FUS is a component of miRISC (miRNA-induced silencing complex) and that overexpression of its truncation mutant R495X negatively impacts miRNA mediated RNA silencing. In this study, we compared the impact overexpression of wild-type myc-tagged FUS versus truncation mutant R495X has on global gene expression. Overall design: Pairwise comparisons were made based on three biological replicates from two groups: 293Ts expressing myc-tagged R495x versus those expressing wild-type myc-tagged FUS. Less...